



To all:

June 11, 2021

SONIRE Therapeutics Inc.

Notice on being selected for “Seed-stage Technology-based Startups” (STS) support  
by New Energy and Industrial Technology Development Organization (NEDO)

SONIRE Therapeutics Inc. (Head office: Shinjuku, Tokyo. President and CEO: Tohru Satoh), with assistance from certified VC Fast Track Initiative, Inc. (Head office: Bunkyo Ward, Tokyo. Representative Director: Hiromichi Kimura), has been selected for “Seed-stage Technology-based Startups” (STS) support by New Energy and Industrial Technology Development Organization (NEDO) for the development of high-intensity focused ultrasound (HIFU) device treatment support systems.

We will use this opportunity to further accelerate the development of next-generation HIFU treatment devices, which are ultra-minimally invasive cancer treatment devices, to bring a new future to cancer patients and their families as soon as possible.

About SONIRE Therapeutics Inc.

We use the technology and know-how built up at Tokyo Women's Medical University, Tohoku University and Tokyo Medical University to develop high-intensity focused ultrasound devices (HIFU devices). Our vision is to bring a new future to cancer patients through acoustic engineering (ultrasound) and our aim is to provide a new treatment method targeted at pancreatic cancer, one of the most difficult cancers to treat. Please see <https://www.sonire-therapeutics.com> for details.

About Fast Track Initiative, Inc. (hereinafter, “FTI”)

FTI Venture Partners is a biotech-focused venture capital firm. It often invests in startups and early stages and supports the establishment of new and highly original companies as well as their gaining of a competitive edge.

Please see <https://www.fti-jp.com> for details.